Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2019
At a glance
- Drugs Avelumab (Primary) ; Eribulin (Primary)
- Indications Adenocarcinoma; Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Jun 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Jun 2019.
- 25 Jun 2018 Status changed from not yet recruiting to recruiting.
- 23 Apr 2018 New trial record